PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
11796502-7	2002	In these cells, hexarelin and EP-80317, but not ghrelin or MK-0677, caused a dose-dependent inhibition of IGF-II-stimulated thymidine incorporation and cell growth at concentrations close to their binding affinity.	EP80317	30-38	insulin like growth factor 2	Homo sapiens	106-112
28018175-13	2016	Predictably, EP-80317 administration reduced both duration and severity of seizures, prevented the increase in FosB/DeltaFosB levels in the first session, and partially counteracted the increase in p-ERK1/2 levels in the third session.	EP80317	13-21	FBJ osteosarcoma oncogene B	Mus musculus	111-115
29018345-0	2017	Involvement of PPARgamma in the Anticonvulsant Activity of EP-80317, a Ghrelin Receptor Antagonist.	EP80317	59-67	peroxisome proliferator activated receptor gamma	Mus musculus	15-24
29018345-0	2017	Involvement of PPARgamma in the Anticonvulsant Activity of EP-80317, a Ghrelin Receptor Antagonist.	EP80317	59-67	growth hormone secretagogue receptor	Mus musculus	71-87
29018345-3	2017	In our study, we challenged the hypothesis that PPARgamma could be involved in the anticonvulsant effects of EP-80317, a ghrelin receptor antagonist.	EP80317	109-117	peroxisome proliferator activated receptor gamma	Mus musculus	48-57
29018345-3	2017	In our study, we challenged the hypothesis that PPARgamma could be involved in the anticonvulsant effects of EP-80317, a ghrelin receptor antagonist.	EP80317	109-117	ghrelin	Mus musculus	121-128
29018345-14	2017	Overall, these results support the hypothesis that PPARgamma is able to modulate seizures and mediates the anticonvulsant effects of EP-80317.	EP80317	133-141	peroxisome proliferator activated receptor gamma	Mus musculus	51-60
28018175-7	2016	To characterize a group in which seizures could be prevented by pharmacological treatment, we also considered pretreatment with the ghrelin receptor antagonist EP-80317 (330 mug/kg).	EP80317	160-168	growth hormone secretagogue receptor	Mus musculus	132-148
28018175-13	2016	Predictably, EP-80317 administration reduced both duration and severity of seizures, prevented the increase in FosB/DeltaFosB levels in the first session, and partially counteracted the increase in p-ERK1/2 levels in the third session.	EP80317	13-21	mitogen-activated protein kinase 3	Mus musculus	200-206
22732396-4	2012	Desacyl ghrelin, hexarelin, EP80317, and GHRP-6 all significantly inhibited ACE activity in vitro; by comparison, the efficacies of ghrelin and MK-0677 were significantly lower, suggesting that ACE-inhibiting activity is unrelated to ligand affinity to GHS-R1a.	EP80317	28-35	angiotensin I converting enzyme	Homo sapiens	76-79
19382238-6	2009	Interestingly, 10(-7) M desacyl-ghrelin, hexarelin, and EP80317 in the nanomolar range effectively counteracted fAbeta(25-35) stimulation of IL-6 mRNA levels, whereas ghrelin was ineffective.	EP80317	56-63	FA complementation group A	Homo sapiens	112-118
19382238-7	2009	Similarly, the effects of fAbeta(25-35) on IL-1beta mRNA levels were attenuated by desacyl-ghrelin, hexarelin, and EP80317, but not ghrelin.	EP80317	115-122	FA complementation group A	Homo sapiens	26-32
19382238-10	2009	We conclude that desacyl-ghrelin, hexarelin, and EP80317 might interfere with fAbeta activation of CD36 in microglia cells.	EP80317	49-56	FA complementation group A	Homo sapiens	78-84